[FOLD] Amicus Therapeutics, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 4.99 Change: 0.46 (10.15%)
Ext. hours: Change: 0 (0%)

chart FOLD

Refresh chart

Strongest Trends Summary For FOLD

FOLD is in the medium-term down -11% below S&P in 6 months.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. It develops enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs), including Fabry disease, Pompe disease, and Mucopolysaccharoidosis Type I (MPS I). The company also develops novel small molecules as monotherapy treatments for Fabry disease and Parkinson's disease. Its chaperone-advanced replacement therapy program is used to develop next-generation ERTs by co-formulating therapeutic enzymes with proprietary pharmacological chaperones. The company?s lead programs include the small molecule pharmacological chaperones, migalastat HCl as a monotherapy that is in Phase III global registration studies for Fabry patients with genetic mutations; and AT2220 (duvoglustat HCl), which has completed Phase II safety used for the treatment of Pompe disease. Its products also comprise AT-B200, a proprietary recombinant human acid-alpha g

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-40.12% ROE-74.29% ROI-61.43%
Current Ratio7.19 Quick Ratio Long Term Debt/Equity0.07 Debt Ratio0.2
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities4.06 M Cash From Investing Activities21.66 M Cash From Operating Activities-20.98 M Gross Profit
Net Profit-24.29 M Operating Profit-24.06 M Total Assets192.62 M Total Current Assets151.25 M
Total Current Liabilities21.02 M Total Debt14.4 M Total Liabilities88.61 M Total Revenue
Technical Data
High 52 week17.09 Low 52 week8.38 Last close12.25 Last change-2.62%
RSI35.01 Average true range0.62 Beta1.18 Volume3.52 M
Simple moving average 20 days-6.53% Simple moving average 50 days-8.64% Simple moving average 200 days0.24%
Performance Data
Performance Week-3.77% Performance Month-4.82% Performance Quart7.27% Performance Half13.64%
Performance Year-23.72% Performance Year-to-date27.87% Volatility daily2.42% Volatility weekly5.4%
Volatility monthly11.07% Volatility yearly38.34% Relative Volume222.44% Average Volume3.04 M
New High New Low


2019-09-07 09:30:01 | Why Is Amicus Therapeutics FOLD Down 18.9% Since Last Earnings Report?

2019-09-04 07:00:00 | Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2019

2019-08-19 09:35:16 | Is Amicus Therapeutics, Inc.'s NASDAQ:FOLD CEO Overpaid Relative To Its Peers?

2019-08-12 10:59:02 | Amicus FOLD Q2 Earnings Match, Stock Falls on Weak Q3 View

2019-08-10 01:30:55 | Amicus Therapeutics Inc FOLD Q2 2019 Earnings Call Transcript

2019-08-09 04:53:04 | Edited Transcript of FOLD earnings conference call or presentation 8-Aug-19 12:30pm GMT

2019-08-08 09:25:01 | Amicus Therapeutics FOLD Reports Q2 Loss, Tops Revenue Estimates

2019-08-08 07:00:00 | Amicus Therapeutics Announces Second Quarter 2019 Financial Results and Corporate Updates

2019-08-02 07:00:00 | Amicus Therapeutics Receives Marketing Authorization for Galafold® migalastat for Fabry Disease in Argentina

2019-08-01 10:33:02 | Analysts Estimate Amicus Therapeutics FOLD to Report a Decline in Earnings: What to Look Out for

2019-08-01 06:00:00 | Amicus Announces Positive Interim Clinical Data for AAV Gene Therapy in Children with CLN6 Batten Disease

2019-07-29 07:00:00 | Amicus Therapeutics to Announce Second Quarter 2019 Financial Results on August 8, 2019

2019-07-22 13:07:00 | New Jersey biotech firm to open Lake Nona office, lab

2019-07-04 13:39:54 | If You Had Bought Amicus Therapeutics NASDAQ:FOLD Stock Five Years Ago, You Could Pocket A 227% Gain Today

2019-07-04 11:51:00 | Why Amicus Therapeutics' Stock Perked Up in June

2019-07-02 07:30:00 | Amicus Therapeutics and Catalent Biologics Enter Strategic Partnership for Gene Therapy Development and Manufacturing

2019-07-01 07:00:00 | Amicus Therapeutics and Brammer Bio, a part of Thermo Fisher Scientific, Enter Strategic Gene Therapy Development and Manufacturing Collaboration

2019-06-19 21:59:00 | Is Amicus Therapeutics, Inc. FOLD A Good Stock To Buy?

2019-06-13 07:30:00 | Amicus Therapeutics Adds Key Executives in Gene Therapy Science and Global Commercial Leadership

2019-06-12 17:49:39 | New Jersey biotech firm scales back Lake Nona plans

2019-06-12 08:44:00 | 2 Small Biotechs With Sagging Shares but Promising Prospects

2019-06-07 09:30:01 | Why Is Amicus Therapeutics FOLD Down 9.6% Since Last Earnings Report?

2019-06-04 16:01:00 | Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock

2019-06-03 07:00:00 | Amicus Therapeutics to Present at Upcoming Scientific and Investor Conferences

2019-05-31 07:34:40 | The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

2019-05-30 21:00:00 | Amicus Therapeutics Prices Underwritten Offering of Common Stock

2019-05-30 16:29:00 | Why NIO, PVH, and Amicus Therapeutics Slumped Today

2019-05-30 14:11:00 | Here's Why Amicus Therapeutics Fell as Much as 15.6% Today

2019-05-30 10:34:00 | 2 Ultra-High-Growth Biotech Stocks to Buy Now

2019-05-30 07:33:27 | The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug

2019-05-29 16:14:50 | Amicus Therapeutics Announces Public Offering of Common Stock

2019-05-29 11:36:45 | Amicus, Penn expand gene therapy collaboration in a big way

2019-05-29 06:30:00 | Amicus Therapeutics and the University of Pennsylvania Announce Major Expansion of Gene Therapy Collaboration

2019-05-24 09:00:02 | Here Are Amicus’s Key Research Programs in 2019

2019-05-24 07:30:29 | How Is Amicus Therapeutics’ Galafold Placed in the First Quarter?

2019-05-23 11:10:02 | Comparing the EPS Trajectory of FOLD and PTLA in Fiscal 2019

2019-05-23 09:40:02 | FOLD and PTLA: What to Expect from Revenue Growth in Fiscal 2019

2019-05-23 08:08:46 | What Are Analysts Recommending for FOLD and PTLA in May?

2019-05-13 17:00:00 | Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors

2019-05-10 07:00:00 | Amicus Therapeutics to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

2019-05-09 15:21:07 | Amicus' FOLD Earnings & Revenues Miss Estimates in Q1

2019-05-08 18:18:09 | Edited Transcript of FOLD earnings conference call or presentation 8-May-19 12:30pm GMT

2019-05-08 16:23:41 | Amicus Therapeutics Inc FOLD Q1 2019 Earnings Call Transcript

2019-05-08 08:25:12 | Amicus Therapeutics FOLD Reports Q1 Loss, Lags Revenue Estimates

2019-05-08 07:24:22 | Amicus Therapeutics: 1Q Earnings Snapshot

2019-05-08 07:00:00 | Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates

2019-05-03 09:51:01 | What's in Store for Catalyst Pharma CPRX Q1 Earnings?

2019-05-01 10:33:02 | Analysts Estimate Amicus Therapeutics FOLD to Report a Decline in Earnings: What to Look Out for

2019-04-30 20:00:00 | 3 Growth Stocks to Buy and Hold for the Next 50 Years

2019-04-30 08:06:00 | The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering